

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Biosion, Inc.</u>  (Last) (First) (Middle) 5TH FLOOR, BUILDING D 3-1 ZHONGDAN UNIT, SOUTH LONGSHAN RD  (Street) NANJING F4 210061  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 11/18/2024	3. Issuer Name and Ticker or Trading Symbol <u>Aclaris Therapeutics, Inc.</u> [ <u>ACRS</u> ]	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Warrants (right to buy)	11/18/2024	(1)	Common Stock <sup>(1)</sup>	11,281,985 <sup>(1)</sup>	0.0001	D	

**Explanation of Responses:**

1. On November 18, 2024, Aclaris Therapeutics, Inc. ("Aclaris") and Biosion, Inc. ("Biosion") entered into a Common Stock Purchase Warrant (the "Warrant"). Pursuant to the Warrant, Biosion, its designee or its permitted assigns, upon meeting certain terms and conditions of the Warrant, is entitled to exercise the warrant for up to 11,281,985 shares of Aclaris Common Stock. The Warrant was exercisable as of November, 18 2024 and may be exercised until the date on which the Warrant is exercised in full.

/s/ Biosion, Inc. by: 11/25/2024  
MINGJIU CHEN, CEO

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**